(Q43884084)

27 November 2017

Design and synthesis of a series of indole glycoprotein IIb/IIIa inhibitors (English)

1 reference

27 November 2017

Valérie Grumel

1

1 reference

27 November 2017

Jean-Yves Mérour

2

1 reference

27 November 2017

Brigitte Lesur

3

1 reference

27 November 2017

Thierry Giboulot

4

1 reference

27 November 2017

Armand Frydman

5

1 reference

27 November 2017

Gérald Guillaumet

6

1 reference

27 November 2017

1 January 2002

1 reference

European Journal of Medicinal Chemistry

27 November 2017

1 reference

27 November 2017

37

1 reference

27 November 2017

45-62

1 reference

27 November 2017

1

1 reference

Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents

27 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2801%2901325-3

7 January 2021

Antithrombotic agents: from RGD to peptide mimetics.

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2801%2901325-3

7 January 2021

Variants of the cell recognition site of fibronectin that retain attachment-promoting activity

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2801%2901325-3

7 January 2021

Design and synthesis of novel cyclic RGD-containing peptides as highly potent and selective integrin alpha IIb beta 3 antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2801%2901325-3

7 January 2021

Conformationally constrained peptides and semipeptides derived from RGD as potent inhibitors of the platelet fibrinogen receptor and platelet aggregation

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2801%2901325-3

7 January 2021

Development of a small RGD peptide fibrinogen receptor antagonist with potent antiaggregatory activity in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2801%2901325-3

7 January 2021

Potent, selective, orally active 3-oxo-1,4-benzodiazepine GPIIb/IIIa integrin antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2801%2901325-3

7 January 2021

From peptide to non-peptide. 3. Atropisomeric GPIIbIIIa antagonists containing the 3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione nucleus

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2801%2901325-3

7 January 2021

Conformational preferences in a benzodiazepine series of potent nonpeptide fibrinogen receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2801%2901325-3

7 January 2021

Orally active non-peptide fibrinogen receptor (GpIIb/IIIa) antagonists: identification of 4-[4-[4-(aminoiminomethyl)phenyl]-1-piperazinyl]-1-piperidineacetic acid as a long-acting, broad-spectrum antithrombotic agent

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2801%2901325-3

7 January 2021

New platelet fibrinogen receptor glycoprotein IIb-IIIa antagonists: orally active series of N-alkylated amidines with a 6,6-bicyclic template

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2801%2901325-3

7 January 2021

New orally active non-peptide fibrinogen receptor (GpIIb-IIIa) antagonists: identification of ethyl 3-[N-[4-[4-[amino[(ethoxycarbonyl) imino]methyl]phenyl]-1,3-thiazol-2-yl]-N-[1-[(ethoxycarbonyl)methyl]pip erid -4-yl]amino]propionate (SR 121787) as

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2801%2901325-3

7 January 2021

Preparation and pharmacological evaluation of novel glycoprotein (Gp) IIb/IIIa antagonists. 1. The selection of naphthalene derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2801%2901325-3

7 January 2021

Preparation and pharmacological evaluation of novel glycoprotein (Gp) IIb/IIIa antagonists. 2. Condensed heterocyclic derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2801%2901325-3

7 January 2021

Design of orally active, non-peptide fibrinogen receptor antagonists. An evolutionary process from the RGD sequence to novel anti-platelet aggregation agents

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2801%2901325-3

7 January 2021

Synthesis and some properties and antitumor effects of the actinomycin lactam analog, (di(1-L-alpha, beta-diaminopropionic))actinomycin D1

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2801%2901325-3

7 January 2021

Synthesis and angiotensin converting enzyme-inhibitory activity of 1,5-benzothiazepine and 1,5-benzoxazepine derivatives. III.

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2801%2901325-3

7 January 2021

10.1016/S0223-5234(01)01325-3

Identifiers

DOI

1 reference

27 November 2017

1 reference